150 related articles for article (PubMed ID: 23278696)
21. Inhibition of intestinal microflora beta-glucuronidase modifies the distribution of the active metabolite of the antitumor agent, irinotecan hydrochloride (CPT-11) in rats.
Takasuna K; Hagiwara T; Hirohashi M; Kato M; Nomura M; Nagai E; Yokoi T; Kamataki T
Cancer Chemother Pharmacol; 1998; 42(4):280-6. PubMed ID: 9744772
[TBL] [Abstract][Full Text] [Related]
22. Involvement of UDP-glucuronosyltransferase activity in irinotecan-induced delayed-onset diarrhea in rats.
Onoue M; Kurita A; Kado S; Matsumoto T; Kaneda N; Uchida K; Kato I; Yokokura T
Cancer Chemother Pharmacol; 2008 Apr; 61(4):595-605. PubMed ID: 17549477
[TBL] [Abstract][Full Text] [Related]
23. Effects of breast cancer resistance protein inhibitors and pharmaceutical excipients on decreasing gastrointestinal toxicity of camptothecin analogs.
Zhang XX; Pan WS; Gan L; Zhu CL; Gan Y
Acta Pharmacol Sin; 2008 Nov; 29(11):1391-8. PubMed ID: 18954535
[TBL] [Abstract][Full Text] [Related]
24. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
[TBL] [Abstract][Full Text] [Related]
25. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
[TBL] [Abstract][Full Text] [Related]
26. Influence of multiple dose activated charcoal on the disposition kinetics of irinotecan in rats.
Balram C; Zhou QY; Cheung YB; Lee EJ
Drug Metabol Drug Interact; 2002; 19(2):137-48. PubMed ID: 12751911
[TBL] [Abstract][Full Text] [Related]
27. St. John's Wort modulates the toxicities and pharmacokinetics of CPT-11 (irinotecan) in rats.
Hu Z; Yang X; Ho PC; Chan E; Chan SY; Xu C; Li X; Zhu YZ; Duan W; Chen X; Huang M; Yang H; Zhou S
Pharm Res; 2005 Jun; 22(6):902-14. PubMed ID: 15948034
[TBL] [Abstract][Full Text] [Related]
28. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
[TBL] [Abstract][Full Text] [Related]
29. Irinotecan (CPT-11) and characteristic mucosal changes in the mouse ileum and cecum.
Ikuno N; Soda H; Watanabe M; Oka M
J Natl Cancer Inst; 1995 Dec; 87(24):1876-83. PubMed ID: 7494232
[TBL] [Abstract][Full Text] [Related]
30. Protective effects of kampo medicines and baicalin against intestinal toxicity of a new anticancer camptothecin derivative, irinotecan hydrochloride (CPT-11), in rats.
Takasuna K; Kasai Y; Kitano Y; Mori K; Kobayashi R; Hagiwara T; Kakihata K; Hirohashi M; Nomura M; Nagai E
Jpn J Cancer Res; 1995 Oct; 86(10):978-84. PubMed ID: 7493918
[TBL] [Abstract][Full Text] [Related]
31. Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea.
Gupta E; Lestingi TM; Mick R; Ramirez J; Vokes EE; Ratain MJ
Cancer Res; 1994 Jul; 54(14):3723-5. PubMed ID: 8033091
[TBL] [Abstract][Full Text] [Related]
32. Adsorption of irinotecan onto oral adsorbent AST-120 (Kremezin) for preventing delayed diarrhea.
Hidaka M; Yamasaki K; Okumura M; Ogikubo T; Iwakiri T; Setoguchi N; Nishida K; Nagai K; Ikenoue T; Arimori K
Cancer Chemother Pharmacol; 2007 Feb; 59(3):321-8. PubMed ID: 16770581
[TBL] [Abstract][Full Text] [Related]
33. Panipenem does not alter the pharmacokinetics of the active metabolite of irinotecan SN-38 and inactive metabolite SN-38 glucuronide (SN-38G) in rats.
Kato A; Ueyama J; Abe F; Hotta K; Tsukiyama I; Oshima T; Kondo F; Saito H; Hasegawa T
Anticancer Res; 2011 Sep; 31(9):2915-22. PubMed ID: 21868538
[TBL] [Abstract][Full Text] [Related]
34. Organic Anion Transporting Polypeptide (OATP)2B1 Contributes to Gastrointestinal Toxicity of Anticancer Drug SN-38, Active Metabolite of Irinotecan Hydrochloride.
Fujita D; Saito Y; Nakanishi T; Tamai I
Drug Metab Dispos; 2016 Jan; 44(1):1-7. PubMed ID: 26526067
[TBL] [Abstract][Full Text] [Related]
35. High-performance liquid chromatographic method for the simultaneous determination of the camptothecin derivative irinotecan hydrochloride, CPT-11, and its metabolites SN-38 and SN-38 glucuronide in rat plasma with a fully automated on-line solid-phase extraction system, PROSPEKT.
Kurita A; Kaneda N
J Chromatogr B Biomed Sci Appl; 1999 Mar; 724(2):335-44. PubMed ID: 10219676
[TBL] [Abstract][Full Text] [Related]
36. Intravenous administration of irinotecan elevates the blood beta-glucuronidase activity in rats.
Kaneda N; Kurita A; Hosokawa Y; Yokokura T; Awazu S
Cancer Res; 1997 Dec; 57(23):5305-8. PubMed ID: 9393754
[TBL] [Abstract][Full Text] [Related]
37. Function of multidrug resistance-associated protein 2 in acute hepatic failure rats.
Yokooji T; Murakami T; Yumoto R; Nagai J; Takano M
Eur J Pharmacol; 2006 Sep; 546(1-3):152-60. PubMed ID: 16899240
[TBL] [Abstract][Full Text] [Related]
38. Dramatic increase in hepatic and biliary curcumin exposure by modulation of its elimination pathway in rats.
Lee JH; Kim HG; Oh JH; Lee YJ
J Pharm Pharmacol; 2013 Mar; 65(3):423-9. PubMed ID: 23356851
[TBL] [Abstract][Full Text] [Related]
39. Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites.
Mallants R; Van Oosterwyck K; Van Vaeck L; Mols R; De Clercq E; Augustijns P
Xenobiotica; 2005; 35(10-11):1055-66. PubMed ID: 16393861
[TBL] [Abstract][Full Text] [Related]
40. Pharmacokinetics of orally administered camptothecins.
Gupta E; Vyas V; Ahmed F; Sinko P; Cook T; Rubin E
Ann N Y Acad Sci; 2000; 922():195-204. PubMed ID: 11193895
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
